USA: New Leadership ISPE Appoints New CEO and President
The International Society for Pharmaceutical Engineering (ISPE) announced that Thomas B. Hartman has been appointed as the CEO and President, effective 1 June 2020.
Tampa/USA — As of June 2020, ISPE will be led by Thomas. B. Hartman as CEO and President. Hartman has an extensive background in the pharmaceutical industry, rising to the role of Vice President of GMP Operations, Biopharm CMC, for Glaxo Smith Kline (GSK).
His executive leadership experience and commitment to product quality, includes all aspects of biopharmaceutical CMC supply chain management. Most recently his team established manufacturing capability for the supply of viral vectors, enabling GSK’s cell and gene therapy platform.
Hartman is experienced in all aspects of biopharmaceutical CMC functions including cell banking, materials management, manufacturing including microbial and mammalian expression systems, and support functions including facility monitoring, engineering, capital project management, validation, and quality control, often leading negotiations with international external supply CMO/CRO’s.
Prior to joining GSK in 2001, he held multiple engineering and operations roles with a major US-based chemical manufacturer, including a five-year expatriate role in the Netherlands and the UK, culminating with responsibilities as head of engineering at a large chemical facility. In his career, Hartman has successfully conducted business in multiple countries including the US, UK, East/West Europe, China, Korea, Singapore, India, and Mexico.
Hartman has been a Member of ISPE since 2001. He has actively participated in the Delaware Valley Chapter and was elected to the ISPE Board of Directors in 2013, most recently serving as the 2019–2020 Vice Chair. He has served on various ISPE committees and was instrumental in starting the ISPE Foundation. He holds a degree in Mechanical Engineering from Villanova University and an MBA from Eastern University.